Physician profile
Douglas Buethe
NPI 1669767315
$823.86
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $24.96 · 2021: $19.70 · 2022: $244 · 2023: $153 · 2024: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $332.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $174.88 | 2019-2023 | Tremfya |
| Dermavant Sciences, INC. | $136.52 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $119.67 | 2019-2024 | |
| Lilly USA, LLC | $101.13 | 2019-2024 | Taltz, Olumiant |
| Abbvie INC. | $68.57 | 2019-2022 | |
| Incyte Corporation | $66.16 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $39.08 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.16 | 2022-2023 | Sotyktu |
| Celgene Corporation | $24.89 | 2019 | |
| Genzyme Corporation | $22.67 | 2019 | |
| Abbott Laboratories | $20.00 | 2019 | |
| Smith+Nephew, INC. | $16.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Buethe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.